A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)
一项随机、双盲、多中心、3 组关键 2/3 期研究,旨在评估玻璃体内注射 EYE103 与玻璃体内注射雷珠单抗 (0.5mg) 相比,对糖尿病黄斑水肿参与者的疗效和安全性
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
研究概览
详细说明
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
研究类型
注册 (实际的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习地点
-
-
-
Be’er Ya‘aqov、以色列、70300
- Beer Yakov, Israel
-
Haifa、以色列、3436212
- Haifa, Israel
-
Jerusalem、以色列、9112001
- Jerusalem, Israel
-
Petah Tikva、以色列、49100
- Petah Tikva, Israel
-
Rehovot、以色列、76100
- Rehovot, Israel
-
Tel Aviv、以色列、6423906
- Tel Aviv, Israel
-
-
-
-
-
Osijek、克罗地亚、31000
- Osijek, Croatia
-
-
-
-
-
Budapest、匈牙利、H-1062
- Budapest, Hungary
-
Budapest、匈牙利、H-1085
- Budapest, Hungary
-
Budapest、匈牙利、H-1106
- Budapest, Hungary
-
Budapest、匈牙利、H-1133
- Budapest, Hungry
-
Debrecen、匈牙利、H-4032
- Debrecen, Hungary
-
Pécs、匈牙利、H-7621
- Pecs, Hungary
-
Szeged、匈牙利、H-6720
- Szeged, Hungary
-
Zalaegerszeg、匈牙利、8900
- Zalaegerszeg, Hungary
-
-
-
-
-
Medellín、哥伦比亚、50016
- Medellin, Colombia
-
-
Antioquia
-
Medellín、Antioquia、哥伦比亚、50021
- Medellin, Colombia
-
-
Atlántico
-
Barranquilla、Atlántico、哥伦比亚、80002
- Barranquilla, Colombia
-
-
Columbia
-
Bogotá、Columbia、哥伦比亚、110231
- Bogota, Columbia
-
-
Valle del Cauca Department
-
Cali、Valle del Cauca Department、哥伦比亚、760042
- Cali, Colombia
-
-
-
-
Turkey
-
Ankara、Turkey、土耳其(türkiye)、06230
- Ankara, Turkey
-
Ankara、Turkey、土耳其(türkiye)、06490
- Ankara, Turkey
-
Balçova、Turkey、土耳其(türkiye)、35330
- Balcova, Turkey
-
-
-
-
-
Graz、奥地利、8036
- Graz, Austria
-
Innsbruck、奥地利、6020
- Innsbruck, Austria
-
Vienna、奥地利、1090
- Vienna, Austria
-
Vienna、奥地利、1140
- Vienna, Austria
-
-
-
-
-
Frankfurt、德国、60590
- Frankfurt, Germany
-
Hanover、德国、30625
- Hanover, Germany
-
München、德国、80336
- Munchen, Germany
-
Münster、德国、48145
- Munster, Germany
-
-
-
-
-
Bologna、意大利、40138
- Bologna, Italy
-
Florence、意大利、50139
- Firenze, Italy
-
Milan、意大利、20122
- Milano, Italy
-
Milan、意大利、20132
- Milano, Italy
-
Milan、意大利、20157
- Milano, Italy
-
Roma、意大利、00168
- Roma, Italy
-
Rome、意大利、81.00133
- Rome, Italy
-
Udine、意大利、33100
- Udine, Italy
-
-
-
-
-
Riga、拉脱维亚、LV1002
- Riga, Latvia
-
Riga、拉脱维亚、LV1006
- Riga, Latvia
-
-
-
-
-
Mladá Boleslav、捷克语、293 01
- Mlada Boleslav, Czechia
-
Náchod、捷克语、547 01
- Nachod, Czechia
-
Prague、捷克语、1150/50
- Prague, Czechia
-
Prague、捷克语
- Prague, Czechia
-
-
-
-
-
Trebišov、斯洛伐克、075 01
- Trebisov, Slovakia
-
Trenčín、斯洛伐克、911 01
- Trencin, Slovakia
-
Žilina、斯洛伐克、012 07
- Zilina, Slovakia
-
-
-
-
-
Créteil、法国、94010
- Creteil, France
-
Lyon、法国、69004
- Lyon, France
-
Marseille、法国、13008
- Marseille, France
-
Paris、法国、75006
- Paris, France
-
Paris、法国、75015
- Paris, France
-
Paris、法国、75019
- Paris, France
-
Saint-Cyr-sur-Loire、法国、37540
- Saint Cyr sur Loire, France
-
-
Cedex
-
Dijon、Cedex、法国、21079
- Cedex, France
-
-
-
-
-
Bialystok、波兰、15-866
- Bialystok, Poland
-
Bydgoszcz、波兰、85-309
- Bydgoszcz, Poland
-
Bydgoszcz、波兰、85-631
- Bydgoszcz, Poland
-
Gdansk、波兰、80-809
- Gdansk, Poland
-
Katowice、波兰、40-594
- Katowice, Poland
-
Krakow、波兰、31-501
- Krakow, Poland
-
Olsztyn、波兰、10-424
- Olsztyn, Poland
-
Tarnowskie Góry、波兰、42-600
- Tarnowskie Gory, Poland
-
-
Gdansk
-
Gdansk、Gdansk、波兰、80-809
- Gdansk, Poland
-
-
-
-
PR
-
Arecibo、PR、波多黎各、00612
- Arecibo, PR
-
-
-
-
-
Albury、澳大利亚、2640
- Albury, Australia
-
Parramatta、澳大利亚、2150
- Parramatta, Australia
-
Sydney、澳大利亚、2000
- Sydney, Australia
-
-
New South Wales
-
Sydney、New South Wales、澳大利亚、2000
- Sydney Retina Clinic
-
Sydney、New South Wales、澳大利亚、2135
- Sydney, Australia
-
-
-
-
Arizona
-
Scottsdale、Arizona、美国、85255
- Scottsdale
-
-
Arkansas
-
Fayetteville、Arkansas、美国、72703
- Fayetteville, Arkansas
-
Springdale、Arkansas、美国、72764
- Springdale, Arkansas
-
-
California
-
Bakersfield、California、美国、93309
- Bakersfield, CA
-
Glendale、California、美国、91204
- Glendale, CA
-
Modesto、California、美国、95356
- Modesto, CA
-
Mountain View、California、美国、94040
- Mountain View, CA
-
Redlands、California、美国、92374
- Redlands, CA
-
Sacramento、California、美国、95825
- Sacramento, CA
-
Sacramento、California、美国、95841
- Sacramento, CA
-
Santa Ana、California、美国、92705
- Santa Ana
-
-
Colorado
-
Colorado Springs、Colorado、美国、80909
- Colorado Springs, CO
-
Denver、Colorado、美国、80210
- Denver, Colorado
-
-
Connecticut
-
Danbury、Connecticut、美国、06810
- Danbury, CT
-
Manchester、Connecticut、美国、06042
- Manchester, CT
-
Waterford、Connecticut、美国、06385
- Waterford,CT
-
-
Florida
-
Deerfield Beach、Florida、美国、33064
- Deerfield Beach, FL
-
Fort Lauderdale、Florida、美国、33308
- Fort Lauderdale, FL
-
Fort Myers、Florida、美国、33912
- Fort Myers,FL
-
Gainesville、Florida、美国、32607
- Gainesville, FL
-
Orlando、Florida、美国、32806
- Orlando, Florida
-
Plantation、Florida、美国、33324
- Plantation, FL
-
Sarasota、Florida、美国、34232
- Sarasota, FL
-
St. Petersburg、Florida、美国、33711
- Saint Petersburg, FL
-
Tallahassee、Florida、美国、32308
- Tallahassee, FL
-
Tampa、Florida、美国、33609-4614
- Tampa, FL
-
Tampa、Florida、美国、33617
- Tampa, FL
-
Winter Haven、Florida、美国、33880
- Winter Haven, FL
-
-
Illinois
-
Lemont、Illinois、美国、60439
- Lemont, IL
-
Springfield、Illinois、美国、62702
- Springfield, Illinois
-
-
Iowa
-
West Des Moines、Iowa、美国、50266
- West Des Moines, IA
-
-
Kansas
-
Lenexa、Kansas、美国、66215
- Lenexa, Kansas
-
Wichita、Kansas、美国、67214
- Wichita, Kansas
-
-
Maine
-
Portland、Maine、美国、04101
- Portland, Maine
-
-
Maryland
-
Hagerstown、Maryland、美国、21740
- Hagerstown, MD
-
-
Massachusetts
-
Springfield、Massachusetts、美国、01107
- Springfield,MA
-
-
Michigan
-
Grand Rapids、Michigan、美国、49546
- Grand Rapids, Michigan
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55435
- Minneapolis, MN
-
-
Mississippi
-
Madison、Mississippi、美国、39110
- Madison, MS
-
-
New Jersey
-
Bloomfield、New Jersey、美国、07003
- Bloomfield, NJ
-
Cherry Hill、New Jersey、美国、08034
- Cherry Hill, NJ
-
-
New York
-
Liverpool、New York、美国、13088
- Liverpool, NY
-
Oceanside、New York、美国、11572
- Oceanside, NY
-
Rochester、New York、美国、14620
- Rochester, NY
-
-
North Carolina
-
Asheville、North Carolina、美国、28803
- Asheville, NC
-
Hickory、North Carolina、美国、28602
- Hickory, NC
-
Wake Forest、North Carolina、美国、27587
- Wake Forest, MC
-
Winston-Salem、North Carolina、美国、27103
- Winston Salem, NC
-
-
Ohio
-
Cleveland、Ohio、美国、44122
- Cleveland, Ohio
-
Cleveland、Ohio、美国、44130
- Cleveland, OH
-
Youngstown、Ohio、美国、44505
- Youngstown, Ohio
-
-
Oklahoma
-
Edmond、Oklahoma、美国、73013
- Edmond, OK
-
-
Oregon
-
Portland、Oregon、美国、97221
- Portland, OR
-
Springfield、Oregon、美国、97477
- Springfield, Oregon
-
-
Pennsylvania
-
Bethlehem、Pennsylvania、美国、18017
- Bethlehem, PA
-
Erie、Pennsylvania、美国、16507
- Erie, PA
-
-
South Carolina
-
Beaufort、South Carolina、美国、29902
- Beaufort, SC
-
Florence、South Carolina、美国、29501
- Florence, SC
-
Ladson、South Carolina、美国、29456
- Ladson, SC
-
West Columbia、South Carolina、美国、29169
- West Columbia, SC
-
-
Tennessee
-
Germantown、Tennessee、美国、38138
- Germantown, TN
-
Hixson、Tennessee、美国、37343
- Hixson, Tennessee
-
Johnson City、Tennessee、美国、37604
- Johnson City, Tennessee
-
Knoxville、Tennessee、美国、37922
- Knoxville, TN
-
Nashville、Tennessee、美国、37203
- Nashville, TN
-
-
Texas
-
Abilene、Texas、美国、79606
- Abilene, TX
-
Amarillo、Texas、美国、79109
- Amarillo, TX
-
Amarillo、Texas、美国、79106
- Amarillo, TX
-
Arlington、Texas、美国、76012
- Arlington, TX
-
Austin、Texas、美国、78705
- Austin, TX
-
Beaumont、Texas、美国、77707
- Beaumont, TX
-
Bellaire、Texas、美国、77401
- Bellaire, TX
-
Dallas、Texas、美国、75231
- Dallas, TX
-
Fort Worth、Texas、美国、76104
- Fort Worth, TX
-
Katy、Texas、美国、77494
- Katy, TX
-
Plano、Texas、美国、75075
- Plano, TX
-
Round Rock、Texas、美国、78681
- Round Rock, TX
-
San Antonio、Texas、美国、78240
- San Antonio, TX
-
Schertz、Texas、美国、78154
- Schertz, Texas
-
The Woodlands、Texas、美国、77384
- The Woodlands, TX
-
Willow Park、Texas、美国、76087
- Willow Park, TX
-
-
Utah
-
Salt Lake City、Utah、美国、84107
- Salt Lake City, Utah
-
-
Virginia
-
Lynchburg、Virginia、美国、24502
- Lynchburg, VA
-
Richmond、Virginia、美国、23235
- Richmond, Virginia
-
-
Washington
-
Spokane、Washington、美国、99204
- Spokane, WA
-
-
-
-
-
Bradford、英国、BD9 6RJ
- Bradford, United Kingdom
-
Bristol、英国、BS1 2LX
- Bristol, UK
-
Liverpool、英国、L7 8YA
- Liverpool, United Kingdom
-
Sunderland、英国、SR2 9HP
- Sunderland, United Kingdom
-
Wolverhampton、英国、WV10 0QP
- Wolverhamptom, United Kingdom
-
-
Middlesex
-
London、Middlesex、英国、NW10 7NS
- London, UK
-
-
UnitedKingdom
-
York、UnitedKingdom、英国、YO10 4DZ
- York, United Kingdom
-
-
-
-
-
Coimbra、葡萄牙、3000-548
- Coimbra, Portugal
-
Coimbra、葡萄牙、3030-163
- Coimbra, Portugal
-
Porto、葡萄牙、4200-319
- Porto, Portugal
-
-
-
-
-
Barcelona、西班牙、08035
- Barcelona, Spain
-
Barcelona、西班牙、08021
- Barcelona, Spain
-
Barcelona、西班牙、08022
- Barcelona, Spain
-
Barcelona、西班牙、08195
- Barcelona, Spain
-
Santiago de Compostela、西班牙、15706
- Santiago de Compostela, Spain
-
Seville、西班牙、41009
- Sevilla, Spain
-
Zaragoza、西班牙、50009
- Zaragoza, Spain
-
-
Valencia
-
Burjassot、Valencia、西班牙、46100
- Valencia, Spain
-
-
-
-
-
CABA、阿根廷、1023
- Buenos Aires, Argentina
-
Córdoba、阿根廷、X5000AAJ
- Ciudad de Cordoba, Argentina
-
-
Buenos Aires
-
CABA、Buenos Aires、阿根廷、1015
- Buenos Aires, Argentina
-
CABA、Buenos Aires、阿根廷、1120
- Buenos Aires, Argentina
-
CABA、Buenos Aires、阿根廷、C1033AAW
- Buenos Aires, Argentina
-
Caba、Buenos Aires、阿根廷、C1116ABA
- Caba, Buenos Aires, Argentina
-
-
Córdoba Province
-
Córdoba、Córdoba Province、阿根廷、5000
- Cordoba, Argentina
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、S2000DSK
- Santa Fe, Argentina
-
-
Sante Fe
-
Rosario、Sante Fe、阿根廷、2000
- Santa Fe, Argentina
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).
Exclusion Criteria:
-
Be pregnant or breastfeeding
-
History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
-
Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
-
Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
-
If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Remigromig Low Dose Treatment Arm
Remigromig Low Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
其他名称:
|
|
实验性的:Remigromig High Dose Treatment Arm
Remigromig High Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
其他名称:
|
|
有源比较器:Ranibizumab Treatment Arm
Ranibizumab Treatment Arm |
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
大体时间:Baseline and Week 52
|
The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Baseline and Week 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
大体时间:Baseline and Week 52
|
The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented. |
Baseline and Week 52
|
|
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
大体时间:Baseline and Week 52
|
The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Time to Absence of Diabetic Macular Edema (DME)
大体时间:Up to approximately Week 104
|
The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented. |
Up to approximately Week 104
|
|
Time to Gaining ≥15 ETDRS letters
大体时间:Up to approximately Week 52
|
The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Up to approximately Week 52
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
大体时间:Up to approximately Week 24
|
The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented. |
Up to approximately Week 24
|
|
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
大体时间:Up to approximately Week 52
|
The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
大体时间:Baseline and Week 52
|
The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
大体时间:Up to approximately Week 52
|
The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
大体时间:Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
大体时间:Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
大体时间:Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 104 Weeks
|
合作者和调查者
调查人员
- 研究主任:Charles Miller, MD PhD、EyeBiotech Ltd.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.